NCT07294664

PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer

Clinical Study of SHR1701 in Combination With CAPOX and SHR2554 or Apatinib for First-line Treatment of Advanced Gastric Cancer

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 78 (estimated)
• Sponsor: The First Affiliated Hospital of Zhengzhou University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Immunotherapy combined with chemotherapy has become the standard first-line treatment regimen for gastric cancer. However, a subset of patients still fail to benefit or derive only limited benefit from this approach. This study aims to evaluate the addition of immunomodulatory EZH2 inhibitors or anti-angiogenic agents to the baseline regimen of immunotherapy combined with chemotherapy, in order to further improve patient treatment benefits.

Conditions

• Advanced Gastric Cancer
• SHR1701

Interventions

Type	Name	Description
DRUG	SHR1701	SHR1701:1800mg,d1,Q3W
DRUG	SHR2554	SHR2554 350mg,bid
DRUG	CAPOX	Capecitabine:1000mg/kg,bid,d1-d14,Q3W Oxaliplatin:130mg/m2,d1,Q3W
DRUG	Apatinib	250 mg, qd

Timeline

• Start date: 2025-06-15
• Primary completion: 2027-07-15
• Completion: 2028-07-15
• First posted: 2025-12-19
• Last updated: 2026-04-16

Locations

1 site across 1 country: China